| INTRODUCTION
Radioactive nuclides have been used in nuclear medicine for the assessment of functional processes since about a century. 1 However, to be suitable for in vivo imaging applications, a radionuclide needs to meet specific physical demands: Its decay radiation should be in an energy range sufficiently high to escape a patient's body in detectable amounts but also low enough to allow an efficient measurement by available detectors. Suitable γ energies for this purpose are usually in the range of 50 to 600 keV for single photon emission computed tomography (SPECT) and 511 keV for positron emission tomography (PET). Furthermore, the physical half-life (t 1/2 ) of the nuclide needs to be on the one hand long enough for a work-up procedure, processing and suitable for the time scale needed to track the biological process of interest, but on the other hand short enough to result in an acceptable radiation burden for the investigated subject. Last but not least, practical radionuclides need to be accessible. Since these requirements are not easily fulfilled, only a relatively small number of radionuclides have made their way into clinical practice. For scintigraphy and SPECT applications, nuclides like indium-111 ( 111 In, t 1/2 = 2.8 d),
iodine-123 ( 123 I, t 1/2 = 13.2 h), and technetium-99m 
(
68 Ga, t 1/2 = 67.6 min) has increasingly found applications as a PET radiometal because of the introduction of 68 Ga generators and the establishment of somatostatinand prostate-specific membrane antigen (PSMA) tracers in the clinic. 2 However, all these PET nuclides have a t 1/2 of 2 to 110 minutes. Therefore, they are not suitable to track compounds in vivo that exhibit a slow pharmacokinetic (several hours to days), such as antibodies, cells, nanoparticles, and liposomes. The number of applications of antibodies radiolabelled with a PET radionuclide (immunoPET) has significantly increased over the last decade. 3 
| Nuclide production
In theory, a large number of nuclear reactions can lead to the formation of each of the different manganese isotopes discussed in this review, including possible side products such as 53 Mn and 54 Mn (see IAEAs EXFOR database). 8 However, many of the reported production routes have no practical relevance, and a comprehensive discussion of all possibilities is beyond the scope of this review. Instead, we focus on the most efficient ones, which includes the irradiation of solid chromium targets. The production of 51 Mn was discussed by Klein et al including a survey of potential nuclear reactions as well as a short summary of previous results by other groups. 9 They concluded that the 50 Cr(d,n) 51 Mn reaction previously investigated by Cogneau et al 10 protons. An isomerically pure production of these nuclides is therefore not possible by this approach. However, for the production of 52g Mn for imaging applications, this is not an issue. Because of the significant difference in t 1/2 of 52g Mn (21.1 min) and 52m Mn (5.6 d), the contamination can be removed by just simply letting the 52m Mn decay. The same applies also to potentially coproduced 51 Mn. The only reported relevant impurity of 52g Mn mentioned in the literature is 54 Mn, which is produced in minor amounts from 54 Cr by a (p,n) reaction. Information about the potential long-living impurity 53 Mn is scarcely discussed albeit considerable cross sections for the 53 Cr(p,n) 53 Mn reaction have been published. 16 However, the formation of both long-living However, because of the poor accessibility of the mother nuclide 52 Fe, this approach has not been fully explored yet. [18] [19] [20] In most of them, the chromium target disc is first dissolved in an acidic medium and flushed over an ion exchange column. The radiomanganese is retained while chromium is washed out of the column. In a next step, the radiomanganese is eluted from the column with a different solvent composition. In the case of insufficient removal of chromium, the procedure has to be repeated. Different ion exchange resins, solvents, and solvent mixtures have been evaluated. For example, a recently published method required multiple subsequent column purifications resulting in a 52g Mn recovery below 70%. 21 Thus, there is still room for future improvements. A further development is the combination of chemical and chromatographic separation techniques, resulting in higher purity of the desired 52g Mn. 22 The different purification conditions are summarized in a review by Chaple et al, 18 although none of them can be considered yet as "perfect" in terms of simplicity and recovery of the radionuclide. It should be noted that, unlike in case of 52g Mn, these elaborate and lengthy separation techniques are not adequate to isolate the short-living manganese PET isotopes 52m Mn and 51 Mn, if produced via a solid chromium target. The development of a suitable liquid target enabling fast separation by solid phase extraction technology might provide a solution (a similar discussion is ongoing regarding the cyclotron production of 68 Ga). 23 In summary, the transition metal manganese offers three isotopes interesting for potential PET applications. Two of those, namely, 51 Mn and 52m Mn, are short living and thus, have the potential for the imaging of fast biological processes. In comparison, 51 Mn is the better candidate because of its favourable decay characteristics (longer t 1/2 , practically no additional γ-rays), which are comparable with those of 68 Ga.
52g Mn, on the other hand, has a suitable half-life for the PET imaging of slow biological processes including applications in immunoPET. However, the presence of several high-energy γ rays with high intensity necessitates the use of suitable corrections in PET imaging and is demanding with regard to radiation protection. 25 Other studied chelators for the complexation of Mn (II) are EDTA 3 and its derivatives such as CDTA 4 (Figure 1 ).
28
Mn (II) in its octahedral high spin complexes owns five unpaired electrons, which results in a high paramagnetic moment. For this reason, manganese (II) complexes have been investigated as possible magnetic resonance imaging (MRI) contrast agents. For example, the dipyridoxyl diphosphate (DPDP) complex of manganese (II) (Teslascan, Figure 2 ) was used in the clinic for the diagnosis of liver lesions. However, the compound has meanwhile been withdrawn from the market because of its insufficient stability in vivo. 29 
| Biological pathways of MnCl 2 in vivo and neuronal connectivity imaging
Manganese is an essential element for all beings, for example, participating in numerous enzymatic processes as a cofactor. 30 In the oxidation states +II and +III, it is transported in the blood bound to serum proteins 31 before it accumulates in organs and tissue or is excreted. 32 Each human body contains roughly 12 mg of manganese mostly stored in the bones, liver, and kidney. 33 Notably, it is also known to cross the blood-brain-barrier. 34 In higher doses, free manganese ions are known to cause a neurological disorder condition called manganism with psychiatric and, in later stages, Parkinson-like symptoms. 35 With regard to potential medical applications of manganese compounds, the pharmacokinetic profile of intravenously injected [
52g Mn]MnCl 2 was investigated in mice. 36 The highest accumulation of the radiometal was found in the liver, kidney, salivary glands, thyroid, and pancreas, whereas only low uptake of radioactivity was observed in the bones. These data may help to predict the fate of Mn (II) ions in case they get released from radiopharmaceuticals in vivo. Interestingly, the biodistribution pattern changed when [ 52g Mn]MnCl 2 was given by inhalation as a saline aerosol (eg, decreased uptake in the bones). 36 To study the uptake and retention of manganese with regard to possible neuroimaging techniques, manganeseenhanced magnetic imaging (MEMRI) as well as PET imaging was utilized by Brunnquell et al. 37 For this pur- 
| Manganese-52g for immunoPET, cell labelling, and ß-cell mass monitoring
The use of radiolabelled antibodies for immunoPET has become an important tool in nuclear oncology. 3, 40 Radiolabelled antibodies offer the advantage of high affinity and specificity. On the other hand, antibodies exhibit slow pharmacokinetics and the time until satisfying tumour uptake and/or tumour-to-background ratios are reached is often too long for other short-living PET radionuclides such as 68 Ga, 18 F, or even 64 Cu. Therefore, the longer-living 89 Zr (t 1/2 = 78.4 h) is currently predominantly used for the labelling of clinically relevant antibodies. 40 However, 52g Mn also offers a suitable t 1/2 for immunoPET applications while displaying a lower β + energy and a higher β + intensity than 89 Zr (Table 3) .
Thus, 52g Mn may represent a promising, alternative radiometal for applications in immunoPET. 41 The first and so far only in vivo study with a 52g Mnlabelled antibody was published in 2015 by Graves et al. 21 For this study, the chelator DOTA was conjugated to the AT1-targeting antibody TRC105 and tested in radiolabelled form for the PET imaging of a breast cancer xenograft mouse model. The chelator DOTA allowed for the 52g Mn-labelling at room temperature (see above), which is a necessary requirement to avoid denaturation of the protein during radiolabelling. Despite a slower blood clearance, the in vivo biodistribution and PET imaging yielded comparable results to a similar 89 Zrlabelled antibody conjugate ( Figure 3 ). The research group used 52g Mn instead of the more common 89 Zr to demonstrate the opportunity of PET imaging at late time points postinjection of the radiotracer and the possibility for triple coincidence PET measurements, 42 a new imaging technology for which 52g Mn has suitable physical properties. A different approach towards radiolabelled liposomes using 52g Mn was published by Jensen et al. 44 In this comparative study, 52g Mn(II) and 64 Cu(II) were prepared as their DOTA chelates and used for both internal loading and surface labelling of liposomes. In vivo biodistribution studies with the 52g Mn-labelled liposome preparations revealed that liposomes with internal 52g Mn-loading had a longer plasma half-life than their surface labelled counterparts. The authors concluded that the reduced blood plasma half-live of the surface modified liposomes could result from insufficient in vivo stability of the radiometal-DOTA chelates. MnCl 2 by ex vivo and in vivo imaging of ß-cell metabolism in type 1 and type 2 diabetes mouse models. 45 Previous work on this topic using MRI and nonradioactive manganese ions as contrast agents showed that the utility of this method was limited by the toxicity of free Mn images indicates highly stable DOTA chelation of 52 Mn 2+ even at late time points. H, heart; K, kidneys; L, liver; T, tumour; Th, thyroid.
Reprinted with permission from Graves et al 21 The authors concluded further that because of the rapid uptake mechanisms, the use of the shorter-living 51 Mn might be a good alternative. This was later confirmed by a subsequent study using [ 
| Relaxivity and stability-manganese for PET/MRI
In the past years, complexes of paramagnetic Mn (II) have been discussed as potential alternatives to the wellestablished, but in some cases, disputed gadoliniumbased contrast agents (eg, Gadopentetat-Dimeglumine, Magnevist). 47, 48 For details on Mn-based MRI contrast agents, the reader is referred to an excellent review on the topic. 49 In addition, the availability of PET nuclides of manganese offers the possibility of isotopically radiolabelled manganese MR contrast agents for use in bimodal PET/MR imaging. Hybrid imaging by PET/MRI has lately received considerable attention in the nuclear medicine and radiology because it combines the high sensitivity PET with the high resolution of MRI. 50 The concept is attractive, however, hampered by the different sensitivities of the modalities: PET allows for the application of very low concentrations of the radioactive substance (10 −9 -10
M) for achieving excellent contrast. In comparison, paramagnetic contrast agents for MRI are applied in millimolar concentrations (one dose of Gd-DTPA, Gadovist: 0.1 mmol/kg body weight). 51 The contradicting requirements of the two modalities for contrast agents can be met by using mixtures of a PET tracers with the respective nonradioactive analogous MRI contrast agent (carrier added radiotracers). Because the PET tracer ( 52g Mn) and the MR contrast agent ( nat Mn) are structurally identical, they exhibit equal biological properties. 52 Employment of such mixtures enables, eg, the quantification of the MR contrast agent in areas of low uptake by PET. Furthermore, the concept is particularly attractive for applications to "smart MR contrast agents". 53, 54 The ability of a coordination compound to enhance longitudinal MR contrast is described by the value "relaxivity" r 1 . The relaxivity of paramagnetic coordination compounds is influenced not only by the number of unpaired electrons of the central metal ion but also by its internal rotation, size, and most importantly, magnetic influence on directly bound and surrounding water molecules. 55 Since a water molecule as an additional ligand inside the coordination sphere of the metal is required for contrast enhancement, Mn (II) complexes with hexa-or lower dentate ligand systems and at least one inner sphere water molecule are potential candidates for MRI contrast agents. 60 The tendency of the chelator DOTA 1 to form octadentate complexes with manganese of excellent stability (see above) has its downside in this context: Because of the lack of an inner sphere water molecule in [ nat Mn (DOTA)], there is no MR contrast (Table 4) .
Therefore, complexes of Mn (II) with DOTA 1 (and DO3A) 28 have good properties for PET imaging but are not suitable for PET/MR applications. While the combination of Mn (II) with DOTA 1 provides stable complexes but no contrast enhancement, the use of other chelators (eg, EDTA 3) results in complexes with appropriate relaxivity but insufficient stability. Therefore, the quest for new chelators that fulfil both requirements is still ongoing. The best compromise between sufficient stability and contrast enhancement described so far was achieved with chelators on the basis of the 1,2-trans-cyclohexyldiaminocarboxylate (CDTA 4) scaffold, for example, PyC3A 5 ( Figure 4 with structure 4-6). 56 89 Zr not only in terms of t 1/2 but also in terms of β + energy, the latter resulting in better resolution of PET images for 52g Mn. On the other hand, a drawback of 52g Mn in comparison with 89 Zr is the occurrence of high-energy γs that will increase the dose rates for the patients, as well as the lack of commercial sources, which currently restricts its use in radiopharmaceutical research.
Because nat Mn (II) is paramagnetic and PET isotopes of the metal are available, isotopically radiolabelled manganese-based PET/MRI contrast agents are within reach. The main challenge is the identification of suitable chelators, which provide manganese complexes of sufficient stability and relaxivity. Different approaches towards the development of such manganese complexes have been reported, but issues regarding the in vivo stability remain to be addressed. In summary, manganese is a versatile transition metal with available isotopes well suited for MR, PET, and PET/MR imaging. Because of the currently limited availability, only a relatively small number of publications describe the production and use of manganese PET radionuclides. However, this may change in the future as in particular 52g Mn has high potential to become a new emerging radiometal for PET and PET/MR applications in nuclear medicine.
